Diagnosis, Treatment, and Prevention of Alzheimer's Disease
Alzheimer's Disease is a predominant neurodegenerative disorder. Alzheimer's disease, and dementia in general, have a strong genetic and family component, the risk of which is increased by environmental factors and/or concomitant diseases.
The medical and scientific team of the International Centre for Neuroscience and Genomic Medicine, led by Dr. Cacabelos, has developed a UNIQUE PROTOCOL for clinical action for the diagnosis, treatment, and prevention of Alzheimer's disease.
GENOMIC MEDICINE and PERSONALISED TREATMENT are the main keys and differentiating elements that place us at the forefront of today's medicine and allow us to carry out more precise and personalised diagnoses.
Diagnosis in a single session
We carry out all the tests required by each person (analytical, neuropsychological, etc.) in a single day to reach an accurate diagnosis.
Alzheimer's Prevention Plan
Programme for identifying the risk of Alzheimer's disease, or other forms of dementia, many years before the first symptoms appear. Allows discrimination of other memory disorders and dementias (vascular, mixed, fronto-temporal, Lewy body).
Alzheimer's disease has no curative treatment and current drugs (donepezil, rivastigmine, galantamine, memantine) are of limited efficacy in preserving memory and are not without toxicity. Work is underway on vaccines, but these will not be available for a decade, so the best form of intervention is considered to be preventive, intercepting the disease before it manifests itself through personalised intervention formulas.
MEDICAL EXAMINATION
LABORATORY ANALYSIS
IMAGING TESTS
DIGITAL DIAGNOSTIC TESTS
NEUROPSYCHOLOGICAL AND PSYCHOMETRIC ASSESSMENT
GENOMIC DIAGNOSIS
PHARMACOGENETIC PROFILE
EPIGENETIC BIOMARKERS
MEDICAL EXAMINATION
- General Examination
- Systemic Review
- Neurological Examination
- Psychiatric Examination
LABORATORY ANALYSIS
- Blood tests:
- Biochemistry
- Blood count
- Metabolism
- Hormones
- Analysis of urine and other body fluids
- Special tests:
- Neurotransmitters
- Tumour markers
- Customised Panels
- Food Intolerances
IMAGING TESTS
- Radiology
- Densitometry
- Magnetic Resonance Imaging
- Computerised Axial Tomography
DIGITAL DIAGNOSTIC TESTS
- Brain Mapping
- Digital Optical Surveying
- Ultrasonography
- Electrophysiology
- Specific Somatosensory Tests by Sense Organs (Vision, Hearing, Smell, Taste, Touch)
- Psychomotor tests
NEUROPSYCHOLOGICAL AND PSYCHOMETRIC ASSESSMENT
- Cognitive Function
- Emotional Status
- Conduct
- Intelligence
- Psychomotricity
GENOMIC DIAGNOSIS
- Global exome (NGS technology)
- Specific diagnostic panels:
- Predictive genomics
- Diagnostic Genomics
- Monogenic Genetic Analysis
PHARMACOGENETIC PROFILE
- Global Pharmacogenetic Profile (PGx-60/4000)
- Pharmacogenetic Profile by Pathology
- Pharmacogenetic Profile by Pharmacological Category
- Pharmacogenetic Profile by Drug
EPIGENETIC BIOMARKERS
- Global DNA methylation
- Expression of Pathogenic Genes
- Expression of FarmaGenes (PharmacoEpiGenetics)
WHAT OUR DIAGNOSTIC PROTOCOL CONSISTS OF
1. Clinical evaluation.
- Initial assessment of the patient.
- Complete medical examination.
2.- Tests to be carried out.
- Complete Blood Evaluation.
- Brain Evaluation:
- Morphological: MRI and CT.
- Functional: Topography, Brain Bioelectrical Activity and Transcranial Doppler.
- Full Body Evaluation: Digestive, Bone, Pulmonary Function, Vascular Examination (Arterial and Venous) and Genitourinary System.
- Cardiovascular evaluation.
- Neuropsychological evaluation.
- Genomic Tracing (*):
- Alzheimer's Genetic Panel.
- Cerebrovascular Disease Genetic Panel.
- Epigenetic Biomarkers: Global Methylation.
- Pharmacogenetics. (Personalised treatment according to your genetics).
- Food Sensitivity Tests.
- Other tests to be determined at the initial medical assessment:
- Neuro - Otorhinolaryngology.
- Neuro - Ophthalmology.
These tests are available to be carried out in advance at your home. Please ask for information.
3. Analysis of the results obtained.
At the end of the testing day, we obtain a clinical diagnosis that allows us to carry out a personalised preventive and/or therapeutic intervention programme for each patient.
4.- Medical report.
Includes all the tests in the diagnostic process and the treatment guidelines to follow based on the patient's pharmacogenetic profile.
This programme is also aimed at:
1.- First- and second-generation relatives with a history of dementia in the family.
2.- People with cardiovascular and/or cerebrovascular diseases that represent risk factors for dementia.
3.- General population from 30-35 years of age who want to know their genetic risk profile.